The endpoint of the primary objective 'to evaluate the reduction in SARS-CoV-2 viral load in nasopharyngeal swabs at D7 in patients hospitalized for COVID-19 and treated either with alisporivir and SOC or SOC alone' is presented in Table 4 1. Viral load in cells taken from nasopharyngeal swabs will be measured using the RT-PCR COVID 19 test based on droplet digital PCR, a method allowing for normalization to the cell content in the sample. Endpoint : VLRR, defined as the proportion of patients with an intra patient decrease of ≥ 1.5 log10 viral load, at D7 compared to Baseline

The endpoint of the primary objective 'to evaluate the reduction in SARS-CoV-2 viral load in nasopharyngeal swabs at D7 in patients hospitalized for COVID-19 and treated either with alisporivir and SOC or SOC alone' is presented in Table 4 1. Viral load in cells taken from nasopharyngeal swabs will be measured using the RT-PCR COVID 19 test based on droplet digital PCR, a method allowing for normalization to the cell content in the sample. Endpoint : VLRR, defined as the proportion of patients with an intra patient decrease of ≥ 1.5 log10 viral load, at D7 compared to Baseline